3 Comments
User's avatar
Keagen Hadley's avatar

Super interesting article, Brooks. Thanks for sharing! I look forward to reading it more fully later this evening when I am not just procrastinating.

Have a great Monday!

Expand full comment
Scott Wagers's avatar

Biomarkers to support increasing Healthcare is where we need to go. However, there needs to be major shifts in the perspectives of the different Healthcare stakeholders to accept treatment or other measures to increase Healthcare.

This biggest challenge will be the studies that generate the evidence to convince regulators.

This is a a good example of what I call a fundable frontier. Achieving such a shift is going to require big projects, consortium projects.

Expand full comment
James | Slack Capital's avatar

Hey Brooks!

Given your interest in Biotech, you might enjoy my recent piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.

Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential

https://www.slack-capital.com/p/exozymes-research-report

Expand full comment